References
- Cole SP, Bhardwaj G, Gerlach JH, et al (1992). Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258, 1650-4. https://doi.org/10.1126/science.1360704
- Dong X, Mumper RJ (2010). Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond), 5, 597-615. https://doi.org/10.2217/nnm.10.35
- Duan Z, Lamendola DE, Duan Y, et al (2005). Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol, 55, 277-85. https://doi.org/10.1007/s00280-004-0878-y
- Filipits M, Malayeri R, Suchomel RW, et al (1999). Expression of the multidrug resistance protein (MRP1) in breast cancer. Anticancer Res, 19, 5043-9.
- Goda K, Fenyvesi F, Bacso Z, et al (2007). Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody. J Pharmacol Exp Ther, 320, 81-8.
- He Y, Bi Y, Hua Y, et al (2011). Ultrasound microbubble-mediated delivery of the siRNAs targeting MDR1 reduces drug resistance of yolk sac carcinoma L2 cells. J Exp Clin Cancer Res, 30, 104. https://doi.org/10.1186/1756-9966-30-104
- Hilgendorf C, Spahn-Langguth H, Rhedin M, et al (2005). Selective downregulation of the MDR1 gene product in Caco-2 cells by stable transfection to prove its relevance in secretory drug transport. Mol Pharm, 2, 64-73. https://doi.org/10.1021/mp049931y
- Hua J, Mutch DG, Herzog TJ (2005). Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Gynecol Oncol, 98, 31-8. https://doi.org/10.1016/j.ygyno.2005.03.042
- Huang C, Li Y, Cao P, Xie Z, Qin Z (2011). Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells. J Huazhong Univ Sci Technolog Med Sci, 31, 488-96. https://doi.org/10.1007/s11596-011-0478-0
- Kroger N, Achterrath W, Hegewisch-Becker S, Mross K, Zander A.R (1999). Current options in treatment of anthracycline-resistant breast cancer. Cancer Treat Rev, 25, 279-91. https://doi.org/10.1053/ctrv.1999.0137
- Kruhn A., Wang A., Fruehauf JH, Lage H (2009). Delivery of short hairpin RNAs by transkingdom RNA interference modulates the classical ABCB1-mediated multidrug-resistant phenotype of cancer cells. Cell Cycle, 8, 3349-54. https://doi.org/10.4161/cc.8.20.9845
- Leonard GD, Fojo T, Bates SE (2003). The role of ABC transporters in clinical practice. Oncologist, 8, 411-24. https://doi.org/10.1634/theoncologist.8-5-411
- Li Y, Yan PW, Huang XE, Li CG (2011). MDR1 gene C3435T polymorphism is associated with clinical outcomes in gastric cancer patients treated with postoperative adjuvant chemotherapy. Asian Pac J Cancer Prev, 12, 2405-9.
- Liu C, Zhao G, Liu J, et al (2009). Novel biodegradable lipid nano complex for siRNA delivery significantly improving the chemosensitivity of human colon cancer stem cells to paclitaxel. J Control Release, 140, 277-83. https://doi.org/10.1016/j.jconrel.2009.08.013
- Liu J, Zhang Y, Xu R, et al (2013). PI3K/Akt-dependent phosphorylation of GSK3beta and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration. Cell Signal, 25, 447-56. https://doi.org/10.1016/j.cellsig.2012.10.012
- O’Driscoll L, Clynes M (2006a). Biomarkers and multiple drug resistance in breast cancer. Curr Cancer Drug Targets, 6, 365-84. https://doi.org/10.2174/156800906777723958
- O’Driscoll L, Clynes M (2006b). Molecular markers of multiple drug resistance in breast cancer. Chemotherapy, 52, 125-9. https://doi.org/10.1159/000092540
- Ozben T (2006). Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett, 580, 2903-9. https://doi.org/10.1016/j.febslet.2006.02.020
- Pan GD, Yang JQ, Yan LN, et al (2009). Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. World J Gastroenterol, 15, 431-40. https://doi.org/10.3748/wjg.15.431
- Song W, Jiang R, Zhao CM (2012). Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells. Asian Pac J Cancer Prev, 13, 5619-25. https://doi.org/10.7314/APJCP.2012.13.11.5619
- Stege A, Kruhn A, Lage H (2010). Overcoming multidrug resistance by RNA interference. Methods Mol Biol, 596, 447-65. https://doi.org/10.1007/978-1-60761-416-6_20
- Szakacs G, Annereau JP, Lababidi S, et al (2004). Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell, 6, 129-37. https://doi.org/10.1016/j.ccr.2004.06.026
- Wang J, Li J, Huang Y, et al (2013). Bcl-3 suppresses Tax-induced NF-kappaB activation through p65 nuclear translocation blockage in HTLV-1-infected cells. Int J Oncol, 42, 269-76. https://doi.org/10.3892/ijo.2012.1685
- Yamauchi M, Kumazawa H, Satta T, et al (1992). Prediction of doxorubicin resistance in gastrointestinal cancer by P-glycoprotein staining. Eur J Cancer, 28A, 1422-7.
- Zhang D, Fan D (2007). Multidrug resistance in gastric cancer: recent research advances and ongoing therapeutic challenges. Expert Rev Anticancer Ther, 7, 1369-78. https://doi.org/10.1586/14737140.7.10.1369
- Zhang KG, Qin CY, Wang HQ, Wang JX, Wang QM (2012). The effect of TRAIL on the expression of multidrug resistant genes MDR1, LRP and GST-pi in drug-resistant gastric cancer cell SGC7901/VCR. Hepatogastroenterology, 59, 2672-6.
Cited by
- Luteolin-loaded Phytosomes Sensitize Human Breast Carcinoma MDA-MB 231 Cells to Doxorubicin by Suppressing Nrf2 Mediated Signalling vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5311
- Establishment and Partial Characterization of an Epirubicin-Resistant Gastric Cancer Cell Line with Upregulated ABCB1 vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6849
- Association between ABCB1 Immunohistochemical Expression and Overall Survival in Gastric Cancer Patients vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6935
- Pemetrexed is Mildly Active with Good Tolerability in Treating Patients with Gastric Cancer vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7137
- EGF Reverses Multi-drug Resistance via the p-ERK Pathway in HepG2/ADM and SMMC7721/ADM Hepatocellular Carcinoma Models vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2619
- Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer vol.33, pp.3, 2014, https://doi.org/10.3892/or.2014.3702
- CIP-36, a novel topoisomerase II-targeting agent, induces the apoptosis of multidrug-resistant cancer cells in vitro vol.35, pp.3, 2014, https://doi.org/10.3892/ijmm.2015.2068
- RNAi-based Knockdown of Multidrug Resistance-associated Protein 1 is Sufficient to Reverse Multidrug Resistance of Human Lung Cells vol.15, pp.24, 2014, https://doi.org/10.7314/APJCP.2014.15.24.10597
- Inhibitory Effects of Phenolic Alkaloids of Menispermum Dauricum on Gastric Cancer in Vivo vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10825
- Transcriptional factor specificity protein 1 (SP1) promotes the proliferation of glioma cells by up-regulating midkine (MDK) vol.26, pp.3, 2015, https://doi.org/10.1091/mbc.E14-10-1443
- Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer vol.142, pp.10, 2016, https://doi.org/10.1007/s00432-016-2167-7
- Genetic Variation in the ABCB1 Gene May Lead to mRNA Level Chabge: Application to Gastric Cancer Cases vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8467
- Influence of Genotype and Haplotype of MDR1 (C3435T, G2677A/T, C1236T) on the Incidence of Breast Cancer - a Case-Control Study in Jordan vol.17, pp.1, 2016, https://doi.org/10.7314/APJCP.2016.17.1.261
- The Pattern of Signatures in Gastric Cancer Prognosis vol.19, pp.6, 2018, https://doi.org/10.3390/ijms19061658
- Forkhead box O3 promotes colon cancer proliferation and drug resistance by activating MDR1 expression pp.23249269, 2019, https://doi.org/10.1002/mgg3.554
- Artemisinin inhibits angiogenesis by regulating p38 MAPK/CREB/TSP-1 signaling pathway in osteosarcoma pp.07302312, 2019, https://doi.org/10.1002/jcb.28424